At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, and is currently being evaluated in a...
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration following positive results from our Phase 2b clinical trial, ENCORE 301, and is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive breast cancer in combination with exemestane, E2112.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.